A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers

ACE-536, a recombinant protein containing a modified activin receptor type IIB, is being developed for the treatment of anemias caused by ineffective erythropoiesis, such as thalassemias and myelodysplastic syndromes. ACE-536 acts through a mechanism distinct from erythropoiesis-stimulating agents t...

Descripción completa

Detalles Bibliográficos
Autores principales: Attie, Kenneth M, Allison, Mark J, McClure, Ty, Boyd, Ingrid E, Wilson, Dawn M, Pearsall, Amelia E, Sherman, Matthew L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173124/
https://www.ncbi.nlm.nih.gov/pubmed/24715706
http://dx.doi.org/10.1002/ajh.23732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173124/
https://www.ncbi.nlm.nih.gov/pubmed/24715706
http://dx.doi.org/10.1002/ajh.23732

Ejemplares similares